Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis-Reference-Cited by-同舟云学术

Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis

Published:2023-01-14 Issue:6 Volume:72 Page:1727-1735
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Wong Alex,Riley Maria,Zhao Songzhu,Wang Jing Gennie,Esguerra Vince,Li Mingjia,Lopez Gabrielle,Otterson Gregory A.,Kendra Kari,Presley Carolyn J.,Wei Lai,Owen Dwight H.,Ho Kevin^ORCID

Funder

National Institute of Aging

LUNGevity Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-023-03373-y.pdf

Reference38 articles.

1. Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. https://doi.org/10.1038/s41467-020-17670-y

2. Tanaka A, Sakaguchi S (2019) Targeting treg cells in cancer immunotherapy. Eur J Immunol 49(8):1140–1146

3. Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 375(19):1823–1833

4. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM (2013) Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133

5. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378(14):1277–1290

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis;The Oncologist;2024-06-17

2. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer;Journal of the National Comprehensive Cancer Network;2023-11

3. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer;Lung Cancer;2023-10

4. Checkpoint Inhibitor-Induced Pneumonitis: Incidence and Management;Current Pulmonology Reports;2023-07-05

5. Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis;Cancer Immunology, Immunotherapy;2023-02-18